Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts

Rheumatology

Volumn 47, Issue 10, 2008, Pages 1554-1558

  Nienhuis, H L ^a   De leeuw, K ^a   Bijzet, J ^a   Smit, A ^a   Schalkwijk, C G ^b   Graaff, R ^a   Kallenberg, C G ^a   Bijl, M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced glycation endproducts; Endothelial activation; Receptor for advanced glycation endproducts; Systemic lupus erythematosus

Indexed keywords

6 N CARBOXYETHYLLYSINE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DICARBOXYLIC AMINO ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; AUTOFLUORESCENCE; BLOOD ANALYSIS; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; HYPOTHESIS; MALE; PRIORITY JOURNAL; SKIN EXAMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TANDEM MASS SPECTROMETRY; ULTRAVIOLET A RADIATION;

ADULT; CASE-CONTROL STUDIES; FEMALE; FLUORESCENCE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYSINE; MALE; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; SKIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 52949115717     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken302     Document Type: Article

References (49)

1. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
2. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angiria in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
3. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 2003; 349:2399-406.
4. de Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006;15:675-82.
5. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation andproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004;11:2767-84.
6. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: A mechanism for producing advanced glycation and products at sites of inflammation. J Clin Invest 1999;104:103-13.
7. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982-6.
8. de Leeuw K, Graaff R, de Vries R et al. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology 2007;46:1551-6.
9. Miyata T, Ishiguro N, Yasuda Y et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 1998;244:45-9.
10. Kume S, Takeya M, Mori T et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am J Pathol 1995;147:654-67.
11. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457-68.
12. Zieman SJ, Melenovsky V, Clattenburg L et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007;25:577-83.
13. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994;94:110-7.
14. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-90.
15. Hanford LE, Enghild JJ, Valnickova Z et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004;279:50019-24.
16. Yonekura H, Yamamoto Y, Sakurai S et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-109.
17. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-31.
18. Bucciarelli LG, Wendt T, Qu W et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-35.
19. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
21. Mulder DJ, Water TV, Lutgers HL et al. Skin autofluorescenoe, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523-35.
22. Meerwaldt R, Graaff R, Oomen PH et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-30.
23. Graaff R, Meerwaldt R, Lutgers HL et al. Instrumentation for the measurement of autofluorescence in human skin. Proc SPIE Int Soc Opt Eng 2005;5692:111-B.
24. Brouwer JL, Bijl M, Veeger NJ, Kluin-Nelemans HC, van der MJ. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to vanous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004;104:143-8.
25. de Leeuw K, Senders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005;64:753-9.
26. Teertink T, Barlo R, Ten Brink HJ, Schalkwijk CG. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dillution tandem mass spectrometry. Clin Chem 2004;50:1222-8.
27. Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology 1999;36:529-34.
28. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus - evidence of increased oxidative stress and dyslipidaemia. Rheumatology 2003;42:758-62.
29. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus arythematosus. Clin Chem Lab Med 2002;40:684-8.
30. Hartog JW, de Vries AP, Bakker SJ et al. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 2006;21:2263-9.
31. Mulder DJ, van Haelst PL, Gross S et al. Skin autofluoresconce is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2008;197:217-23.
32. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994;70:138-51.
33. Yanagisawa K, Makita Z, Shiroshita K et al. Specific fluorescence assay for advanced glycation and products in blood and urine of diabetic patients. Metabolism 1998;47:1348-53.
34. Weiss MF, Erhard P, Kader-Attie FA et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000;57:2571-85.
35. Sugiyama S, Miyata T, Ueda Y et al. Plasma levels of pentosidine in diabetic patients: An advanced glycation end product. J Am Soc Nephrol 1998;9:1681-8.
36. Wagner Z, Wittmann I, Mazak I et al. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function. Am J Kidney Dis 2001;38: 785-91.
37. Schmidt AM, Hasu M, Popov D et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994;91:8807-11.
38. Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005;83:876-86.
39. Basta G, Lazzerini G, Massaro M et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;106:816-22.
40. Nakamura K, Yamagishi S, Adochi H et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13:185-9.
41. Pullerits R, Brisslert M, Jonsson IM, Tarkoweski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006;54:3898-907.
42. Taniguchi N, Kawahara K, Yone K et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48:971-81.
43. Gross S, van Ree RM, Oterdoom LH et al. Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients, Transplantation 2007;84:659-63.
44. Falcone C, Emanuele E, D'Angelo A et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005;25:1032-7.
45. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE Inhibition in experimental diabetic naphropathy. Diabetes 2002;51:3274-82.
46. Miyata T, Van Ypersele de SC, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-87.
47. Nakamura K, Yamagishi S, Nakamura Y et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005;70:137-41.
48. Forbes JM, Thorpe SR, Thallas-Bonke V et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363-72.
49. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Synovial fluid expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis. Rheumatology 2007;46:1367-71.